Kailera Therapeutics, Inc. KLRA
13.80 USD +0.10 (+0.73%)
Nov 10, 2026, 9:39 AM EST
13.39 Day range 13.90
9.76 52-week range 28.23
- YTD
- -46.92%
- 1 year
- -46.92%
News
globenewswire.com Kailera Therapeutics to Present at ObesityWeek 2026 Ribupatide injection Phase 3 KaiNETIC trial design presentations highlight its potential to address diverse needs across the obesity spectrum Real-world obesity management presentation highlights the…
benzinga.com Canaccord Genuity Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $44 Canaccord Genuity analyst Edward Nash initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $44.
benzinga.com Kailera Therapeutics Q3 EPS $(0.74) Beats $(1.02) Estimate Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(1.02) by 27.45 percent.
globenewswire.com Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program…
globenewswire.com Kailera Therapeutics to Participate in November Investor Conferences Ron Renaud, President and Chief Executive Officer, and additional members of the management team will participate in the following investor conferences
benzinga.com Kailera Therapeutics Completes Enrollment In KaiNETIC Global Phase 3 Clinical Program; Topline Data Now Expected In Mid-2028 - Ribupatide injection (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m² or higher- Topline data now expected in mid-2028WALTHAM,…
benzinga.com Jim Cramer Recommends Buying This Energy Stock, Calling It ‘Very Inexpensive’ Jim Cramer favors Texas Pacific Land, calls Kailera his speculative pick, and criticizes P&G, Ondas and Tractor Supply.- benzinga.com Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47.3 percent.
benzinga.com Why Is Kailera Therapeutics Stock Falling Tuesday? Kailera Therapeutics oral GLP-1 meets Phase 3 targets for obesity and diabetes. KLRA stock falls 9% on reported GI side effects.- benzinga.com Kailera Therapeutics Announces Topline Data From Two Additional Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535 Conducted By Hengrui Pharma In China In Phase 3 trial in obesity/overweight in China, HRS-7535 achieved a mean weight loss of up to 10.9% at Week 44 and a mean weight loss of up to 11.1% at Week 50 Kailera currently conducting global…
benzinga.com Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(3.65) per share which missed the analyst consensus estimate of $(0.68) by 444.78 percent as R&D spend Jumps to $70.9M.
benzinga.com This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.
benzinga.com Hengrui Pharma, Kailera Therapeutics To Present Two Abstracts At 86th Scientific Sessions Of The American Diabetes Association Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), an advanced clinical-stage biotechnology…
benzinga.com Leerink Partners Initiates Coverage On Kailera Therapeutics with Outperform Rating, Announces Price Target of $36 Leerink Partners analyst David Risinger initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Outperform rating and announces Price Target of $36.- benzinga.com Jefferies Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $48 Jefferies analyst Roger Song initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $48.
- benzinga.com Evercore ISI Group Initiates Coverage On Kailera Therapeutics with Outperform Rating Evercore ISI Group analyst Umer Raffat initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Outperform rating.
benzinga.com This Southwest Gas Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts change outlook on top names. Check their ratings & price targets for AVEX, ALMR, TNDM, SWX, KLRA. See what they think of SWX stock.
benzinga.com JP Morgan Initiates Coverage On Kailera Therapeutics with Overweight Rating, Announces Price Target of $30 JP Morgan analyst Hardik Parikh initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Overweight rating and announces Price Target of $30.
benzinga.com Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy 
benzinga.com Kailera Therapeutics Debut Marks Largest Biotech IPO Since 2021 Amid Weight Loss Race Kailera Therapeutics prices $625 million IPO, advances GLP-1 obesity pipeline as trial data highlights oral ribupatide weight loss results.